Sahzene Yavuz, MD
Endocrinology, Diabetes & Metabolism · Sayre, PANPI 1003054248
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,007 of the $3,765 with a category attached, or 79.9%. 22 manufacturers reported payments, led by Eli Lilly at 31.2% of the total. Reporting peaked in 2024 at $1,854 and has fallen 70.6% since, to $545 in 2025.
Across 108 payments — averaging $34.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- Amgen$572
- Dexcom, Inc.$316
- Lilly USA, LLC$218
- Tandem Diabetes Care, Inc.$217
- Novo Nordisk$196
- plus $1K from 16 others
Across 39 payments — averaging $8700.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$289K
- Eli Lilly$50K
What the payments were for
- Travel & lodging$75020%
- Food & beverage$3,00780%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 24 | $1,175 |
| Amgen | 17 | $572 |
| Dexcom, Inc. | 9 | $316 |
| Lilly USA, LLC | 9 | $218 |
| Tandem Diabetes Care, Inc. | 4 | $217 |
| Novo Nordisk | 8 | $196 |
| Medtronic | 4 | $146 |
| IBSA Pharma Inc. | 1 | $122 |
| Sanofi-aventis U.S. LLC | 4 | $118 |
| Ascensia Diabetes Care US Inc. | 6 | $113 |
| Insulet Corporation | 4 | $105 |
| BETA Bionics, Inc. | 3 | $102 |
| Exelixis Inc. | 1 | $87 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| AbbVie | 3 | $46 |
| Abbott | 2 | $45 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Boehringer Ingelheim | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$132
- t:slim X2 Insulin Pump with Control-IQ$129
- Tirosint$122
- Prolia$121
- DEXCOM G6 TRANSMITTER$118
How this compares
$3,765 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $209,807 |
| MounjaroTirzepatide | 104 | $185,628 |
| Teriparatide | 31 | $98,477 |
| JardianceEmpagliflozin | 55 | $80,601 |
| TrulicityDulaglutide | 50 | $78,965 |
| ForteoTeriparatide | 18 | $74,093 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $37,388 |
| ProliaDenosumab | 22 | $37,225 |
| FarxigaDapagliflozin Propanediol | 16 | $26,950 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $24,798 |
| Novolog FlexpenInsulin Aspart | 52 | $18,380 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $15,788 |
| NovologInsulin Aspart | 46 | $14,123 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $13,971 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $12,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $218 | $342,628190 claims |
| Novo NordiskOzempic, Novolog | $196 | $223,930185 claims |
| Boehringer IngelheimJardiance | $24 | $80,60155 claims |
| AmgenProlia | $572 | $37,22522 claims |
| AstraZenecaFarxiga | $22 | $26,95016 claims |
| AbbVieSynthroid, Armour Thyroid | $46 | $6,32567 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $5,803331 claims |
| IBSA Pharma Inc.Tirosint | $122 | $2,08815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Sayre
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.